Urate-lowering therapy following a treat-to-target continuation strategy compared to a treat-to-avoid-symptoms discontinuation strategy in gout patients in remission (GO TEST Finale): study protocol of a multicentre pragmatic randomized superiority trial

[1]  A. Doney,et al.  Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial , 2022, The Lancet.

[2]  N. Dalbeth,et al.  Critical appraisal of serum urate targets in the management of gout , 2022, Nature Reviews Rheumatology.

[3]  F. Meyer,et al.  Uric Acid Expression in Carotid Atherosclerotic Plaque and Serum Uric Acid Are Associated With Cerebrovascular Events , 2022, Hypertension.

[4]  J. S. Lee,et al.  Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial , 2022, RMD Open.

[5]  N. Dalbeth,et al.  Are we asking the right questions about urate‐lowering therapy? Comment on the 2021 Asia‐Pacific League of Associations for Rheumatology clinical practice guideline for treatment of gout , 2022, International journal of rheumatic diseases.

[6]  L. Joosten,et al.  Trained immunity and inflammation in rheumatic diseases. , 2022, Joint bone spine.

[7]  M. Kolber,et al.  Treat‐to‐Target in Gout Management? Comment on the Article by FitzGerald et al , 2020, Arthritis & rheumatology.

[8]  H. Ahn,et al.  OP0168 CARDIOVASCULAR EVENT ASSOCIATED WITH INITIATING ALLOPURINOL AND FEBUXOSTAT - ACUTE GOUT ATTACK AND CARDIOVASCULAR GOUT ATTACK , 2020 .

[9]  G. Guyatt,et al.  2020 American College of Rheumatology Guideline for the Management of Gout , 2020, Arthritis care & research.

[10]  A. Boonen,et al.  Comparative Study of Real‐Life Management Strategies in Gout: Data From Two Protocolized Gout Clinics , 2020, Arthritis care & research.

[11]  L. Joosten,et al.  Urate‐induced immune programming: Consequences for gouty arthritis and hyperuricemia , 2019, Immunological reviews.

[12]  G. Feuchtner,et al.  Dual-Energy Computed Tomography Detection of Cardiovascular Monosodium Urate Deposits in Patients With Gout. , 2019, JAMA cardiology.

[13]  I. Hisatome,et al.  Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy , 2019, European heart journal.

[14]  L. Duley,et al.  Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial , 2018, The Lancet.

[15]  P. Souverein,et al.  Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD) , 2018, Rheumatology.

[16]  Liren Li,et al.  Rate of adherence to urate-lowering therapy among patients with gout: a systematic review and meta-analysis , 2018, BMJ Open.

[17]  Kenneth G Saag,et al.  Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout , 2018, The New England journal of medicine.

[18]  J. Singh,et al.  Brief Report: Validation of a Definition of Flare in Patients With Established Gout , 2018, Arthritis & rheumatology.

[19]  B. Giraudeau,et al.  Effects of Discontinuation of Urate-Lowering Therapy: A Systematic Review , 2018, Journal of General Internal Medicine.

[20]  Per Winkel,et al.  When and how should multiple imputation be used for handling missing data in randomised clinical trials – a practical guide with flowcharts , 2017, BMC Medical Research Methodology.

[21]  K. Jordan,et al.  The British Society for Rheumatology Guideline for the Management of Gout. , 2017, Rheumatology.

[22]  Zhaokun Ma,et al.  Serum uric acid levels in patients with Parkinson’s disease: A meta-analysis , 2017, PloS one.

[23]  N. Câmara,et al.  Soluble Uric Acid Activates the NLRP3 Inflammasome , 2017, Scientific Reports.

[24]  A. Qaseem,et al.  Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians. , 2017, Annals of internal medicine.

[25]  M. Weisman,et al.  Treat-to-target (T2T) recommendations for gout , 2016, Annals of the rheumatic diseases.

[26]  F. Becce,et al.  2016 updated EULAR evidence-based recommendations for the management of gout , 2014, Annals of the rheumatic diseases.

[27]  K. Jordan,et al.  The British Society for Rheumatology Guideline for the Management of Gout. , 2017, Rheumatology.

[28]  A. Ogdie,et al.  Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises , 2016, Arthritis care & research.

[29]  A. Ogdie,et al.  2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative , 2015, Annals of the rheumatic diseases.

[30]  V. Bhole,et al.  Medication Adherence in Gout: A Systematic Review , 2014, Arthritis care & research.

[31]  F. Becce,et al.  SAT0531 Updated Eular Evidence-Based Recommendations for the Management of Gout , 2014 .

[32]  Liang Shen,et al.  Low uric acid levels in patients with Parkinson's disease: evidence from meta-analysis , 2013, BMJ Open.

[33]  E. Pascual,et al.  Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout , 2007, Annals of the rheumatic diseases.

[34]  J. Nolla,et al.  Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study. , 2006, Arthritis and rheumatism.

[35]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[36]  F. Perez-Ruiz,et al.  Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. , 2002, Arthritis and rheumatism.

[37]  R. Newcombe,et al.  Interval estimation for the difference between independent proportions: comparison of eleven methods. , 1998, Statistics in medicine.